stockrow
Saturday 7 November 2026
Export NUVB’s income statement to Excel — free account
Nuvation Bio Inc.
NUVB Healthcare Biotechnology
Nuvation Bio Inc.’s revenue for fiscal 2025 (year ended December 2025) was $62.9 million, up 699.0% from fiscal 2024.
- Revenue
- +242.6%
- EPS
- +25.6%
- Free cash flow
- +34.1%
- Total debt
- +441.5%
Quarter to September 2026, against a year earlier
4.17
0.02
−0.48%
Follow NUVB
Alert me
Target Price Range
Analyst price targets
Free accountTen years at a glance Fiscal years to December
| Ten-year view | Analyst estimates Powerpack | |||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Group | Line | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM Sep ’26 | Trend | 10 yrs | 2026e | 2027e | 2028e | Next 3/yr |
| Income, $m | ||||||||||||||||||
| Income, $m | Revenue | — | — | — | — | — | — | — | — | 8 | 63 | 202 | +699.0% | 202 | 259 | 418 | +87.9% | |
| Gross margin, % | — | — | — | — | 0.00 | 0.00 | 0.00 | — | 10.10 | 85.22 | 85.79 | +85.2 pt | ||||||
| EBT | — | — | — | — | (42) | (87) | (104) | (76) | (568) | (205) | (136) | +37.5% | ||||||
| EBT margin, % | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | (7,213.76) | (325.31) | (67.38) | (325.3) pt | ||||||
| Net income | — | 0 | — | 0 | (42) | (87) | (104) | (76) | (568) | (205) | (136) | n/m | ||||||
| Per share, $ | ||||||||||||||||||
| Per share, $ | Revenue | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.03 | 0.18 | 0.57 | n/m | |||||
| Earnings | — | — | — | — | (0.43) | (0.44) | (0.48) | (0.35) | (2.11) | (0.60) | (0.39) | +7.0% | ||||||
| Cash flow | — | — | — | — | (0.37) | (0.34) | (0.44) | (0.31) | (0.49) | (0.51) | (0.30) | +6.3% | ||||||
| Capex | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | (0.02) | (0.01) | +74.8% | ||||||
| Free cash flow | — | — | — | — | (0.38) | (0.35) | (0.45) | (0.31) | (0.49) | (0.53) | (0.31) | +7.2% | ||||||
| Book value | — | — | — | — | 2.21 | 3.77 | 3.02 | 2.76 | 1.73 | 0.90 | 0.65 | (16.5%) | ||||||
| Shares, m | — | — | — | — | 98 | 198 | 217 | 219 | 269 | 342 | 347 | +28.5% | ||||||
| Valuation, × | ||||||||||||||||||
| Valuation, × | P/E | — | — | — | — | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.0 | |||||
| P/S | — | — | — | — | — | — | — | — | 0.00 | 48.65 | 7.27 | 24.3 | ||||||
| P/B | — | — | — | — | — | — | — | — | 1.54 | 10.01 | 6.44 | 5.8 | ||||||
| EV/Sales | — | — | — | — | — | — | — | — | 0.00 | 41.08 | 5.40 | 20.5 | ||||||
| EV/FCF | — | — | — | — | — | — | — | — | (1.69) | (14.87) | (10.07) | (8.3) | ||||||
| Cash, $m | ||||||||||||||||||
| Cash, $m | Operating cash flow | — | — | — | — | (37) | (68) | (96) | (68) | (130) | (173) | (106) | +36.6% | |||||
| Capex | — | — | — | — | 0 | 0 | 0 | 0 | 0 | (8) | (2) | +125.0% | ||||||
| Free cash flow | — | — | — | — | (37) | (68) | (96) | (68) | (131) | (182) | (108) | +37.7% | ||||||
| Balance, $m | ||||||||||||||||||
| Balance, $m | Working capital | — | — | — | — | 214 | 755 | 654 | 602 | 468 | 489 | 636 | +18.0% | |||||
| Net debt | — | — | — | — | (216) | (762) | (657) | (611) | (496) | (476) | (378) | +17.2% | ||||||
| Shareholders’ equity | — | — | — | — | 215 | 746 | 655 | 605 | 464 | 306 | 228 | +7.3% | ||||||
| Returns, % | ||||||||||||||||||
| Returns, % | ROA | — | — | — | 0.00 | (37.57) | (17.41) | (14.39) | (11.72) | (97.74) | (36.04) | (19.70) | (36.0) pt | |||||
| ROIC | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.0 pt | ||||||
| ROE | — | — | — | — | (8.67) | (18.07) | (14.87) | (12.03) | (106.27) | (53.18) | (49.09) | (44.5) pt | ||||||
| People | ||||||||||||||||||
| People | Employees | — | — | — | 5 | 36 | 64 | 53 | 51 | 220 | 298 | — | +97.6% | |||||
| Revenue/emp, $m | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.04 | 0.21 | — | n/m | ||||||
Negative figures in brackets.
estimates
Fiscal years to Dec 2025 · latest quarter Sep 2026 · fundamentals updated 6 Nov 2026
Nuvation Bio Inc. vs peers in Biotechnology (Q) = latest quarter vs a year earlier
| Company | Market cap | P/E | Fwd P/E | Revenue growth (Q) | EPS growth (Q) | FCF growth (Q) | Gross margin (Q) | EBIT margin (Q) | Compare |
|---|---|---|---|---|---|---|---|---|---|
| RARE Ultragenyx Pharmaceutical Inc. | $1.5B | — (loss-making) | — (loss-making) | +8.13% (above 0%: growing) | n/m | +12.50% (above 0%: growing) | 81.50% | (63.58%) | Compare |
| NBTX Nanobiotix S.A. - Sponsored ADR | $1.5B | — (loss-making) | — | −71.69% (below 0%: shrinking) | n/m | −177.26% (below 0%: shrinking) | 0.00% | 0.00% | Compare |
| PGEN Precigen, Inc. | $1.5B | 60.3× | 32.2× | +2,437.58% (above 0%: growing) | n/m | +140.34% (above 0%: growing) | 91.22% | 52.13% | Compare |
| NUVB Nuvation Bio Inc. | $1.5B | — (loss-making) | — (loss-making) | +242.61% (above 0%: growing) | n/m | +34.07% (above 0%: growing) | 73.46% | (93.90%) | |
| ADRX ADARx Pharmaceuticals, Inc. | $1.5B | — | — | — | — | — | — | — | Compare |
| IMCR Immunocore Holdings PLC Sponsored ADR | $1.5B | — (loss-making) | — (loss-making) | −1.42% (below 0%: shrinking) | n/m | +440.97% (above 0%: growing) | 99.34% | (13.31%) | Compare |
| QURE uniQure N.V. | $1.5B | — (loss-making) | — (loss-making) | +40.39% (above 0%: growing) | n/m | +27.66% (above 0%: growing) | 95.46% | (1,019.63%) | Compare |
| TYRA Tyra Biosciences, Inc. | $1.4B | — (loss-making) | — | — | n/m | −31.34% (below 0%: shrinking) | 0.00% | 0.00% | Compare |
| AAPG Ascentage Pharma Group International - Unsponsored ADR | $1.4B | — | — | — | — | +17.74% (above 0%: growing) | — | — | Compare |
| Median of peers | $1.5B | — | — | +8.13% | — | +17.74% | 86.36% | (6.65%) |
Pay and ownership Proxy statement filed 10 April 2026
Chief executive’s pay
| Year | Total pay | Actually paid | $100 invested |
|---|---|---|---|
| 2025 | 3.88m | 27.83m | 76.58 |
| 2024 | 3.72m | 6.54m | 22.74 |
| 2023 | 4.32m | 2.79m | 12.91 |
Total pay is as the Summary Compensation Table states it; actually paid revalues the year’s share awards
at its end, as the SEC’s pay-versus-performance rule asks. $100 invested is what $100 in the company’s
shares at the start of the earliest year shown was worth at each year’s end.
Read the proxy statement